When will the FDA approve Intellia Therapeutics' lonvo-z?
As of Wed, 16 Sep 2026 17:10:00 UTC, Kalshi traders price Before October 2027 (91.0%), Before 2028 (91.0%), Before July 2027 (89.0%). The market has $7K in volume and closes on Sat, 01 Jan 2028.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before October 2027 | 91.0% | 91.0¢ | 9.0¢ |
| Before 2028 | 91.0% | 91.0¢ | 9.0¢ |
| Before July 2027 | 89.0% | 89.0¢ | 11.0¢ |
Market details
- Venue: Kalshi
- Volume: $7K
- Liquidity: $7K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for Before October 2027:
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.
Sources
Related markets
- How many launches will SpaceX have in September?
- Tesla Optimus released this year?
- How many launches will SpaceX have this year?
- How many launches will SpaceX have in October?
- When will any company achieve AGI?
- When will Apple release the iPhone 18?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.